Engineering vascularized muscle tissue

• US 20060198827A1
• Filed: 02/03/2006
• Published: 09/07/2006
• Est. Priority Date: 02/04/2005
• Status: Abandoned Application

• Current Assignee: Massachusetts Institute of Technology
• Original Assignee: Massachusetts Institute of Technology
• Inventors: Rouwkema, Jeroen, Levenberg, Shulamit, Langer, Robert S.
• Application Number:
  US11/347,831
• Publication Number:
  US 20060198827A1
• Time in Patent Office: Days
• US Class Current: 424/93.7
• CPC Class Codes: C12N 2502/28 Vascular endothelial cells
• CPC Class Codes: C12N 5/0657 Cardiomyocytes; Heart cells
• CPC Class Codes: C12N 5/0658 Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
• CPC Class Codes: C12N 5/0697 Artificial constructs associating cells of different lineages, e.g. tissue equivalents blood vessels C12N5/0691

Abstract

A tissue engineered construct. The construct includes endothelial cells, muscle cells, and a three-dimensional support matrix on which the endothelial cells and the myoblasts are seeded.

Claims

1. A tissue engineered construct, comprising:

endothelial cells;

muscle cells; and

a three-dimensional support matrix on which the endothelial cells and the muscle are seeded.

2. The construct of claim 1, wherein the construct promotes the formation of one or more of smooth, skeletal, and cardiac muscle tissue.

3. The construct of claim 1, wherein the endothelial cells are embryonic stem cell-derived endothelial cells or umbilical vein endothelial cells;

4. The construct of claim 2, wherein the embryonic stem cell-derived endothelial cells are mammalian embryonic stem cell-derived endothelial cells.

5. The construct of claim 2, wherein the embryonic stem cell-derived endothelial cells are human embryonic stem cell-derived endothelial cells.

6. The construct of claim 2, wherein the umbilical vein endothelial cells are human or mouse umbilical vein endothelial cells.

7. The construct of claim 1, wherein the endothelial cells are mammalian aortic endothelial cells.

8. The construct of claim 1, wherein the muscle cells are mammalian myoblasts.

9. The construct of claim 1, wherein the muscle cells are human or mouse myoblasts.

10. The construct of claim 1, wherein the muscle cells are cardiomyocytes.

11. The construct of claim 1, wherein the muscle cells are skeletal muscle cells.

12. The construct of claim 1, wherein the muscle cells are smooth muscle cells.

13. The construct of claim 1, further comprising fibroblasts.

14. The construct of claim 13, wherein the fibroblasts are embryonic fibroblasts.

15. The construct of claim 13, wherein the fibroblasts are human or mouse embryonic fibroblasts.

16. The construct of claim 1, wherein the three-dimensional support matrix comprises a mixture of poly(L-lactic acid) and poly(lactic acid-co-glycolic acid).

17. The construct of claim 1, wherein the three-dimensional support matrix comprises a 50:

50 mixture of poly(L-lactic acid) and poly(lactic acid-co-glycolic acid).

18. The construct of claim 1, wherein the three-dimensional support matrix is biodegradable or non-biodegradable.

19. The construct of claim 18, wherein the three-dimensional support matrix comprises collagen-GAG, collagen, fibrin, PLA, PGA, PLA-PGA co-polymers, poly(anhydrides), poly(hydroxy acids), poly(ortho esters), poly(propylfumerates), poly(caprolactones), polyamides, polyamino acids, polyacetals, biodegradable polycyanoacrylates, biodegradable polyurethanes and polysaccharides, polypyrrole, polyanilines, polythiophene, polystyrene, polyesters, non-biodegradable polyurethanes, polyureas, poly(ethylene vinyl acetate), polypropylene, polymethacrylate, polyethylene, polycarbonates, poly(ethylene oxide), co-polymers of the above, mixtures of the above, and adducts of the above.

20. The construct of claim 1, wherein the three-dimensional support matrix further comprises a coating including an agent that promotes cell adhesion.

21. The construct of claim 20, wherein the agent that promotes cell adhesion is selected from fibronectin, integrins, and oligonucleotides that promote cell adhesion.

22. The construct of claim 1, wherein the cells are combined with growth-factor reduced Matrigel.

23. The construct of claim 1, further comprising a gel that coats internal and external surfaces of the three-dimensional support matrix.

24. The construct of claim 23, wherein the gel is selected from collagen gel, alginate, agar, growth factor-reduced Matrigel, and MATRIGEL™

.

25. The construct of claim 23, wherein the gel further comprises one or more of laminin, fibrin, fibronectin, proteoglycans, glycoproteins, glycosaminoglycans, chemotactic agents, or growth factors.

26. The construct of claim 1, further comprising VEGF.

27. The construct of claim 1, further comprising a growth factor.

28. The construct of claim 27, wherein the growth factor is selected from activin-A (ACT), retinoic acid (RA), epidermal growth factor, bone morphogenetic protein, TGF-β

, hepatocyte growth factor, platelet-derived growth factor, TGF-β

, IGF-I, IGF-II, hematopoietic growth factors, heparin binding growth factor, peptide growth factors, erythropoietin, interleukins, tumor necrosis factors, interferons, colony stimulating factors, acidic and basic fibroblast growth factors, nerve growth factor (NGF), and muscle morphogenic factor.

29. A tissue-engineered muscle construct, comprising:

a three-dimensional support matrix;

a plurality of myotubes disposed within the support matrix; and

at least one endothelial vessel structure disposed within the support matrix.

30. The construct of claim 29, wherein the endothelial vessel structure comprises at least one vessel-like structure having a lumen.

31. A tissue-engineered muscle construct, comprising:

a three-dimensional support matrix;

a plurality of cardiac muscle cells disposed within the support matrix; and

at least one endothelial vessel structure disposed within the support matrix.

32. The construct of claim 31, wherein the endothelial vessel structure comprises at least one vessel-like structure having a lumen.

33. A method of producing a tissue engineered construct, comprising:

providing a population of endothelial cells;

providing a population of muscle cells;

seeding the endothelial cells and the muscle cells on a three-dimensional support matrix; and

culturing the seeded cell support matrix in a predetermined medium for a predetermined period of time.

34. The method of claim 33, wherein seeding comprises suspending the muscle cells and the endothelial cells in growth-factor reduced Matrigel and absorbing a predetermined amount of the suspension into the three-dimensional support matrix.

35. The method of claim 33, wherein the predetermined medium includes one or more of myoblast medium, endothelial cell medium, cardiac cell medium, and embryonic fibroblast medium.

36. The method of claim 35, wherein the myoblast medium comprises DMEM containing 10% fetal bovine serum, 10% calf serum, and 2.5% HEPES buffer.

37. The method of claim 35, wherein cardiac cell medium comprises DMEM containing 10% fetal calf serum and 1% HEPES buffer.

38. The method of claim 35, wherein embryonic fibroblast medium comprises DMEM containing 10% fetal calf serum.

39. The method of claim 35, further comprising supplementing the medium with VEGF.

40. The method of claim 33, wherein the endothelial cells are embryonic stem cell-derived endothelial cells or umbilical vein endothelial cells.

41. The method of claim 40, wherein the embryonic stem cell-derived endothelial cells are mammalian embryonic stem cell-derived endothelial cells.

42. The method of claim 40, wherein the embryonic stem cell-derived endothelial cells are human embryonic stem cell-derived endothelial cells.

43. The method of claim 40, wherein the umbilical vein endothelial cells are human or mouse umbilical vein endothelial cells.

44. The method of claim 33, wherein the endothelial cells are mammalian aortic endothelial cells.

45. The method of claim 33, wherein the muscle cells are mammalian myoblasts.

46. The method of claim 33, wherein the muscle cells are human or mouse myoblasts.

47. The method of claim 33, wherein the muscle cells are cardiomyocytes.

48. The method of claim 33, wherein the muscle cells are smooth muscle cells.

49. The method of claim 33, wherein the muscle cells are skeletal muscle cells.

50. The method of claim 33, wherein the method further comprises providing a population of fibroblasts and wherein seeding comprises seeding the fibroblasts with the endothelial cells and the myoblasts on the three-dimensional support matrix.

51. The method of claim 50, wherein the fibroblasts are mammalian embryonic fibroblasts.

52. The method of claim 50, wherein the fibroblasts are human or mouse embryonic fibroblasts.

53. The method of claim 33, wherein the three-dimensional support matrix comprises a mixture of poly(L-lactic acid) and poly(lactic acid-co-glycolic acid).

54. The method of claim 33, wherein the three-dimensional support matrix comprises a 50:

50 mixture of poly(L-lactic acid) and poly(lactic acid-co-glycolic acid).

55. The method of claim 33, wherein the three-dimensional support matrix is biodegradable or non-biodegradable.

56. The method of claim 55, wherein the three-dimensional support matrix comprises collagen-GAG, collagen, fibrin, PLA, PGA, PLA-PGA co-polymers, poly(anhydrides), poly(hydroxy acids), poly(ortho esters), poly(propylfumerates), poly(caprolactones), polyamides, polyamino acids, polyacetals, biodegradable polycyanoacrylates, biodegradable polyurethanes and polysaccharides, polypyrrole, polyanilines, polythiophene, polystyrene, polyesters, non-biodegradable polyurethanes, polyureas, poly(ethylene vinyl acetate), polypropylene, polymethacrylate, polyethylene, polycarbonates, poly(ethylene oxide), co-polymers of the above, mixtures of the above, and adducts of the above.

57. The method of claim 33, wherein the three-dimensional support matrix further comprises a coating including an agent that promotes cell adhesion.

58. The method of claim 57, wherein the agent that promotes cell adhesion is selected from fibronectin, integrins, and oligonucleotides that promote cell adhesion.

59. The method of claim 33, wherein seeding comprises suspending the muscle cells and the endothelial cells in a gel and absorbing a predetermined amount of the suspension into the three-dimensional support matrix.

60. The method of claim 59, wherein the gel is selected from collagen gel, alginate, agar, growth factor-reduced Matrigel, and MATRIGEL™

.

61. The method of claim 59, wherein the gel further comprises one or more of laminin, fibrin, fibronectin, proteoglycans, glycoproteins, glycosaminoglycans, chemotactic agents, or growth factors.

62. The method of claim 59, further comprising supplementing the medium with a growth factor.

63. The method of claim 62, wherein the growth factor is selected from activin-A (ACT), retinoic acid (RA), epidermal growth factor, bone morphogenetic protein, TGF-β

, hepatocyte growth factor, platelet-derived growth factor, TGF-α

, IGF-I, IGF-II, hematopoietic growth factors, heparin binding growth factor, peptide growth factors, erythropoietin, interleukins, tumor necrosis factors, interferons, colony stimulating factors, acidic and basic fibroblast growth factors, nerve growth factor (NGF), and muscle morphogenic factor.